Supplementary Materials

Supplementary Material for:

CD99 is a therapeutic target on disease stem cells in myeloid malignancies

Stephen S. Chung, William S. Eng, Wenhuo Hu, Mona Khalaj, Francine E. Garrett-Bakelman, Montreh Tavakkoli, Ross L. Levine, Martin Carroll, Virginia M. Klimek, Ari M. Melnick, Christopher Y. Park*

*Corresponding author. Email: christopher.park{at}nyumc.org

Published 25 January 2017, Sci. Transl. Med. 9, eaaj2025 (2017)
DOI: 10.1126/scitranslmed.aaj2025

This PDF file includes:

  • Fig. S1. CD99 is expressed in comparable amounts on adult BM HSCs and CB HSCs.
  • Fig. S2. CD99 is highly expressed on bulk AML blasts and further increased on LSC-enriched populations.
  • Fig. S3. CD99 expression distinguishes leukemic cells from residual normal or preleukemic HSPCs.
  • Fig. S4. CD99-negative CD34+CD38 cells from AML specimens lack the full complement of mutations present in bulk AML cells.
  • Fig. S5. CD99-positive CD34+CD38 AML cells engraft a lethal myeloid leukemia.
  • Fig. S6. CD99 expression enriches for functional LSCs.
  • Fig. S7. LSC-enriched AML cells with high expression of CD99 demonstrate improved survival in vitro.
  • Fig. S8. FACS purification effectively separates CD99-high and CD99-low LMPP-like cells from primary AML specimens.
  • Fig. S9. FACS purification effectively separates CD99-high and CD99-low bulk unfractionated AML blasts.
  • Fig. S10. CD99-high and CD-low AML blasts often exhibit differing frequencies of variant transcripts.
  • Fig. S11. Other described LSC markers are not enriched on LSC-enriched LMPP-like AML cells.
  • Fig. S12. Anti-CD99 mAbs selectively deplete CD34+CD38 or CD34+ cells from primary AML patient samples.
  • Fig. S13. Anti-CD99 mAb induces apoptosis in MOLM13 cells.
  • Fig. S14. Xenografted AML blasts express cell surface markers characteristic of human AML.
  • Fig. S15. Anti-CD99 mAb clone 10D6 is directly cytotoxic to MOLM13 cells.
  • Fig. S16. Expression of constitutively active SRC causes cell cycle arrest in anti-CD99 mAb–sensitive but not mAb-resistant cells.
  • Table S1. Clinical characteristics of primary MDS BM specimens.
  • Table S2. Clinical characteristics of primary AML specimens.
  • Table S3. Primers used for Sanger sequencing of CD99-negative methylcellulose colonies.

[Download PDF]